Epidemiology Forecast on Excessive Daytime Sleepiness to 2030 – Risks, Burdens and Unmet Needs of EDS – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–Feb 16, 2021–
The "Excessive Daytime Sleepiness (EDS) – Epidemiology Forecast to 2030" report has been added to ResearchAndMarkets.com’s offering.
This report delivers an in-depth understanding of the EDS, historical and forecasted epidemiology as well as the EDS trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
Excessive Daytime Sleepiness (EDS) Disease Understanding
Excessive daytime sleepiness (EDS) is characterized by a difficulty to stay awake and alert during the major waking episodes of the day, with sleep occurring unintentionally or at inappropriate times of the wake period. EDS is often associated with a wide range of illnesses including metabolic, cardiovascular, neurological, psychiatric diseases but also with voluntary behaviors reflecting poor sleep and sleep debt, leading to disability and increased risk of mortality. EDS is also commonly associated with social and economic consequences thus constituting a significant public health problem.
Epidemiology Perspective
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Diagnosed Prevalent Cases of EDS and Total Diagnosed Prevalent Cases of EDS in Different Disorder scenario of EDS in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2030.
Excessive Daytime Sleepiness (EDS) Detailed Epidemiology Segmentation

  • In the epidemiology report, the research team have considered major indications in which EDS occurs, such as Parkinson’s disease (PD), Narcolepsy, Idiopathic Hypersomnia (IH), Obstructive Sleep Apnea (OSA), and Bipolar Disorder.
  • The total diagnosed prevalent population of EDS in these five disorders in the 7MM was estimated to be 6,295,782 in 2017.
  • The total diagnosed prevalent cases of EDS in the US were 2,960,518 in 2017.
  • In the US, the majority of the cases of EDS are found in OSA and Bipolar disorder, followed by Parkinson’s Disease, Narcolepsy, and Idiopathic Hypersomnia.
  • Among the European countries, Germany had the highest diagnosed prevalent population of EDS with 590,827 cases, followed by France which had a diagnosed prevalent population of 487,146 in 2017. On the other hand, Italy had the lowest diagnosed prevalent population.
  • The total diagnosed prevalent cases of EDS in Japan were 1,410,155 in 2017. The highest cases were estimated in OSA, followed by Bipolar Disorder. There were about 1,177,957 EDS cases diagnosed in OSA, followed by 149,322 EDS cases in Bipolar Disorder. The diagnosed EDS cases in other disorders were 47,419 in Narcolepsy, 1,600 in IH, and 33,857 in PD.

Scope of the Report

  • The report covers the descriptive overview of EDS, explaining its causes and diagnosis.
  • The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
  • The report assesses the disease risk and burden and highlights the unmet needs of EDS.
  • The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.
  • The report provides the segmentation of the disease epidemiology for 7MM by Total Diagnosed Prevalent Cases of EDS and Total Diagnosed Prevalent Cases of EDS in Different Disorder.

Report Highlights

  • 11-Year Forecast of EDS
  • 7MM Coverage
  • Total Diagnosed Prevalent Cases of EDS
  • Total Diagnosed Prevalent Cases of EDS in Different Disorder

Key Questions Answered

  • What are the disease risk, burdens, and unmet needs of EDS?
  • What is the historical EDS patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan?
  • What would be the forecasted patient pool of EDS at the 7MM level?
  • What will be the growth opportunities across the 7MM with respect to the patient population pertaining to EDS?
  • Out of the above-mentioned countries, which country would have the highest prevalent population of EDS during the forecast period (2020-2030)?
  • At what CAGR the population is expected to grow across the 7MM during the forecast period (2020-2030)?

Reasons to Buy
The EDS report will allow the user to –

  • Develop business strategies by understanding the trends shaping and driving the 7MM EDS epidemiology forecast.
  • The EDS epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists.
  • The EDS epidemiology model developed by the publisher is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the eleven-year forecast period using reputable sources.

For more information about this report visit https://www.researchandmarkets.com/r/8euu0h
View source version on businesswire.com:https://www.businesswire.com/news/home/20210216005576/en/
CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
KEYWORD:
INDUSTRY KEYWORD: HEALTH OTHER HEALTH
SOURCE: Research and Markets
Copyright Business Wire 2021.
PUB: 02/16/2021 05:13 AM/DISC: 02/16/2021 05:13 AM
http://www.businesswire.com/news/home/20210216005576/en